more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

Top 33% (82 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Zacks News

Coronavirus Spreads Rapidly Worldwide: Medtech Stocks in Focus

by Aparajita Dutta Published on March 04,2020

The coronavirus outbreak disrupts manufacturing and supply chain in China, which in turn might have taken a toll on U.S. Medtech stocks.

medical

Medical Products Industry Outlook: Growth Prospects Bright

by Trina Mukherjee Published on February 28,2020

Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.

medical

3 Medical Product Stocks Likely to Beat This Earnings Season

by Trina Mukherjee Published on February 13,2020

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Sonoco (SON) Meets Q4 Earnings Estimates

by Zacks Equity Research Published on February 13,2020

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Integer Holdings Stock for Now

by Zacks Equity Research Published on February 11,2020

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales. However, intense competition remains a woe.

medical

Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline

by Zacks Equity Research Published on February 05,2020

Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.

Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More

by Zacks Equity Research Published on February 05,2020

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Boston Scientific (BSX) Q4 Earnings Top Estimates

by Zacks Equity Research Published on February 05,2020

Boston Scientific (BSX) delivered earnings and revenue surprises of 4.55% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

BSXNegative Net Change

HRC vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on January 30,2020

HRC vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on January 29,2020

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BSXNegative Net Change

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

by Zacks Equity Research Published on January 29,2020

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

Medical Products' Jan 30 Earnings Roster: TMO, EW & More

by Zacks Equity Research Published on January 29,2020

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More

by Urmimala Biswas Published on January 28,2020

A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.

COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus

by Sriparna Ghosal Published on January 24,2020

Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.

medical

What's in Store for Varian Medical (VAR) in Q1 Earnings?

by Zacks Equity Research Published on January 23,2020

Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.

medical

Boston Scientific Gets a Boost From New Products, Buyouts

by Zacks Equity Research Published on January 17,2020

Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.